Increased risk of myopathy w/ fibric acid & derivatives, lipid-modifying doses of niacin, cyclosporine or strong CYP3A4; other fibrates; colchicine. Increased AUC w/ clarithromycin; HIV-PIs (lopinavir, ritonavir, saquinavir, darunavir, fosamprenavir, tipranavir) & hepatitis C-PIs (telaprevir); itraconazole; OCs (norethindrone & ethinyl estradiol). Increased plasma conc w/ excessive grapefruit juice (>1.2 L/day). Increased bioavailability w/ OATP181 inhibitors (eg, cyclosporine). Increased risk of myopathy/rhabdomyolysis w/ gemfibrozil. May enhance risk of skeletal muscle effects w/ niacin. Reduced plasma conc w/ CYP450 3A4 (eg, efavirenz, rifampin). May increase plasma conc of digoxin.